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Abstract
Objectives Pompe disease is a progressive metabolic myopathy for which enzyme replacement therapy (ERT) was approved in
2006. While various publications have examined the effects of ERT in classic-infantile patients and in adults, little has been
published on ERT in children with non-classic presentations.
Study design This prospective study was conducted from June 1999 to May 2015. Seventeen patients from various countries
participated. Outcome measures comprised muscle function (6-minute walk test, quick motor-function test (QMFT)), muscle
strength (hand-held dynamometry; manual muscle testing), and lung function (FVC sitting and supine). For each outcome
measure, we used linear mixed-effects models to calculate the difference at group level between the start of therapy and 7 years
of ERT. Patients’ individual responses over time were also evaluated.
Results Eleven males and six females started ERT at ages between 1.1 and 16.4 years (median 11.9 years); 82% of them carried
the common c.-32-13T >G GAA gene variant on one allele. At group level, distance walked increased by 7.4 percentage points
(p < 0.001) and QMFT scores increased by 9.2 percentage points (p = 0.006). Muscle strength scores seemed to remain stable.
Results on lung function were more variable. Patients’ individual data show that the proportion of patients who stabilized or
improved during treatment ranged between 56 and 69% for lung function outcomes and between 71 and 93% for muscle strength
and muscle function outcomes.
Conclusions We report a positive effect of ERT in patients with childhood Pompe disease at group level. For some patients, new
or personalized treatments should be considered.
Keywords Pompe disease . Acidmaltase deficiency . Childhood . Enzyme replacement therapy . ERT . Long-term follow-up
Abbreviations
6MWT 6-Minute walk test
6MWT-PP 6-Minute walk test–percentage of predicted
ERT Enzyme replacement therapy
FVC Forced vital capacity
HHD Hand-held dynamometry
MMT Manual muscle testing
MRC Medical research council
pp Percentage point
QMFT Quick motor-function test
Introduction
Pompe disease (OMIM # 232300) is a progressive metabolic
disorder that was first described by the Dutch pathologist J.C.
Pompe in 1932 (Pompe 1932). It is caused by deficiency of
the lysosomal enzyme acid α-glucosidase (GAA). This defi-
ciency results in intracellular glycogen accumulation, mainly
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in muscle cells, and gives rise to a broad clinical spectrum
dominated by skeletal muscle weakness (Hirschhorn and
Reusser 2001; van der Ploeg and Reuser 2008).
At the most severe end of the spectrum, classic-infantile
patients present with hypertrophic cardiomyopathy and gen-
eral muscle weakness. Without enzyme replacement therapy
(ERT), these infants usually die within the first year of life
(van den Hout et al 2003; Kishnani et al 2006). More slowly
progressive forms of Pompe disease can manifest in children
and adults, with onset ranging from early infancy until (late)
adulthood. These presentations are characterized by limb-
girdle and respiratory muscle weakness, resulting in ventilator
and/or wheelchair dependency. The heart is rarely involved
(Engel et al 1973; Laforet et al 2000; Slonim et al 2000; Van
der Beek et al 2009; van der Beek et al 2011; Gungor and
Reuser 2013). While there are similarities between children
and adults with these non-classic presentations, there are also
differences, especially in terms of disease severity. Our recent
cross-sectional study of 31 untreated children with non-classic
presentations showed that 25% needed a wheelchair during
childhood, 48% had decreased pulmonary function, 25%
needed respiratory support, and two died before reaching
adulthood (van Capelle et al 2016).
In 2006, ERT with alglucosidase alfa was approved for
patients with Pompe disease. ERT has been shown to reverse
the hypertrophic cardiomyopathy and increase survival in
classic-infantile patients (Van den Hout et al 2000; Kishnani
et al 2007). In adult patients, positive effects were also dem-
onstrated on endurance, muscle strength, pulmonary function,
and survival (Bembi et al 2010; Strothotte et al 2010; van der
Ploeg et al 2010; Angelini et al 2012; de Vries et al 2012;
Regnery et al 2012; van der Ploeg et al 2012; Anderson et al
2014; Stepien et al 2016; Van Der Ploeg et al 2017). However,
as not all of these patients respond equally well, it has been
speculated that ERTshould be started early to provide the best
result (Strothotte et al 2010; van der Ploeg et al 2010; Angelini
et al 2012; de Vries et al 2012).
Here, we present the long-term follow-up during ERT (me-
dian of 6.8 years) of 17 children with Pompe disease of vari-
ous severity. The longest follow-up after start of ERT was
15 years.
Methods
Patients and study design
This prospective study included children with a confirmed
diagnosis of Pompe disease in whom ERT had been initiated
before the age of 18 years. Patients with classic-infantile
Pompe disease were excluded (Gungor and Reuser 2013),
i.e., those who had hypertrophic cardiomyopathy and started
treatment before the first year of life. The study was conducted
at the Center for Lysosomal and Metabolic Diseases at
Erasmus MC University Medical Center in Rotterdam, the
Netherlands. This is the national referral center for all Dutch
patients with Pompe disease. In addition, patients from outside
the Netherlands have been treated and followed here as part of
trials. The study included 12 patients from the Netherlands,
two from Belgium, one from Germany, and one each from the
UK and the USA.
All but two patients were treated with 20 mg/kg
alglucosidase alfa every other week. Initially, patients 9 and
17 received recombinant human alpha-glucosidase from
transgenic rabbit milk, starting at 10 mg/kg weekly and
ramping up to 20 mg/kg weekly (Winkel et al 2004). After
approximately 3 years, they were switched to infusions of
20mg/kg every other week and later to 30 and 40mg/kg every
other week recombinant human alpha-glucosidase derived
from Chinese hamster ovarian cells, respectively (van
Capelle et al 2008). Only patients with symptoms of skeletal
muscle weakness and/or reduced pulmonary function could
start ERT. None of the included patients were detected via
newborn screening, but some patients were detected early on
in their disease for example because of an affected sibling.
As part of a standardized protocol, outcome assessments
were performed every 3–6 months by trained physical thera-
pists and clinicians. Data were collected prospectively from
June 1999 toMay 2015. Beforemarket approval in 2006, ERT
was given as part of open-label trials (Winkel et al 2004; van
Capelle et al 2010). The initial follow-up of patients 9 and 17
was described by Winkel et al 2004, while patients 3, 5, 11,
12, and 15 participated in a 3-year open-label study described
by van Capelle et al 2010. In addition, patient 16 was included
in the international randomized controlled trial (van der Ploeg
et al 2010). The medical ethical committee approved the pro-
tocol. All patients and/or their parents provided informed
consent.
Motor outcomes
Muscle function was assessed using the 6-minute walk test
(6MWT) and quick motor-function test (QMFT). The
6MWT was performed according to American Thoracic
Society (ATS) guidelines (A. T. S. Committee on
Proficiency Standards for Clinical Pulmonary Function
Laboratories 2002). Throughout follow-up, patients 3, 5,
11, 12, and 15 performed a running variant rather than the
standard 6MWT (van Capelle et al 2010). The percentage
of predicted meters walked (6MWT-PP) was calculated on
the basis of gender-matched and age-matched healthy
peers (Ulrich et al 2013). The QMFT consists of 16 motor
tasks that are specifically difficult to perform for Pompe
patients and was presented as the percentage of the maxi-
mum achievable score (maximum scores indicate normal
movement) (van Capelle et al 2012).
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Muscle s t reng th was assessed by Hand-Held
Dynamometry (HHD; CITEC dynamometer, Centre for
Innovative Technics, Groningen, the Netherlands) and
Manual Muscle Testing (MMT; Medical Research Council
(MRC) grading scale), as described previously (Medical
Research Council 1978; Beenakker et al 2001; van Capelle
et al 2016). The following muscle groups were assessed with
HHD: neck flexors, shoulder abductors, elbow flexors, elbow
extensors, wrist extensors, hip flexors, hip abductors, knee
extensors, knee flexors, and foot dorsal flexors. MMT was
performed for the same groups, with the addition of neck
extensors, hip extensors, hip adductors, and foot plantar
flexors. HHD was presented as age and gender adjusted per-
centage predicted (Beenakker et al 2001); MRC as a percent-
age of the maximum score (the maximum score of 5 indicates
normal strength for age).
Lung function
Forced vital capacity (FVC) was measured in sitting and su-
pine positions according to European Respiratory Society and
ATS guidelines, and was presented as a percentage of the
predicted FVC, corrected for height, gender and ethnicity
(American Thoracic Society/European Respiratory Society
2002; Quanjer et al 2012). A percentage below 80% of the
predicted value was considered abnormally low.
Statistical analyses
To describe disease progression under treatment, we assessed
the development of each of the six outcome measures over
time at group level, and also evaluated them for each patient
individually. We did not perform a power calculation before
embarking on this study, because we set out to describe the
entire population of childhood cases seen in the center.
At group level, we report the change in the estimated mean
outcome measures between baseline and 7 years of treatment
(median follow-up was 6.8 years). To account for the correla-
tions between the repeated measurements of individual pa-
tients, we used the framework of linear mixed-effects models.
Time was expressed as years after start of ERT. To account for
potential non-linear profiles we used natural cubic splines in
the fixed-effects part and random-effects part of the model,
with a maximum of 3 degrees of freedom. For the random-
effects part of the model, we used an unstructured covariance
matrix. If they improved the goodness of fit of a model sig-
nificantly (likelihood-ratio test; p < 0.05), gender and age at
start of ERT were included.
As only one patient had been treated for more than 10 years
(pt.9, treated 15.1 years), models were based on all available
data until 10 years of ERT. Residual plots were inspected to
check the models’ assumptions. The nlme package of R (ver-
sion 3.2.1) was used (Pinheiro et al 2015; R Core Team 2015).
Multiple testing correction was applied according to the Holm
method (Holm 1979).
For individual patients, plots of the outcome measures over
time were assessed by four independent researchers and cate-
gorized as improvement, improvement followed by stabiliza-
tion, stabilization, improvement followed by decline, or de-
cline. Supplemental Fig. 1 gives examples of plots of individ-
ual patients following these different patterns.
Results
Study population
During the study period, 19 children started ERT before their
18th birthday. Two were excluded on the basis that they were
too young (2 and 3 years old at the end of the study) to per-
form any of the assessments used as outcome measures in this
study. Table 1 provides the characteristics and main clinical
findings at start of ERT of the 17 patients included. Eleven
patients were male; age at start of ERT ranged from 1.1 to
16.4 years (median 11.9 years); age at first symptoms ranged
from 0.5 to 13 years (median 2.5 years); and age at diagnosis
ranged from 0.0 to 14.0 years (median 3 years). Treatment
delays were mostly due to ERT not being available at the time
of diagnosis, while a few patients were not yet symptomatic at
diagnosis. Fourteen patients carried the common c.-32-13 T >
G mutation on one allele. Patients had been treated for a me-
dian of 6.8 years (range 1.8 to15.1 years of ERT). No patients
died during follow-up. Eight became adults (18+) during the
study period; at his last assessment, the oldest and longest-
treated patient (pt.9) was 27 years old. ERTwas generally well
tolerated by patients.
At start of therapy, symptoms ranged from mild motor de-
lays to wheelchair and ventilator dependency. One patient
(pt.10) also had hypertrophic cardiomyopathy (left ventricular
mass index, LVMI = 145 g/m2 body surface), which normal-
ized within 12months of treatment (LVMI = 69 g/m2). She was
fed via percutaneous gastrostomy and was fully wheelchair and
ventilator dependent at start of ERT at the age of 12 years. One
further patient was wheelchair and ventilator dependent (pt.17)
at start of ERT; one was wheelchair dependent only (pt.9); and
one needed respiratory support only (pt.15).
Motor outcomes
Muscle function
Fourteen patients were able to perform the 6MWT at regular
intervals. The three others were wheelchair bound. No patients
lost the ability to walk during follow-up. One wheelchair-
bound patient (pt.9) regained the ability to walk 1.5 years after
starting ERT at the age of 13, but was not tested with the
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6MWT until he had received 11 years of ERT (van Capelle
et al 2008). Between 11 and 15 years of ERT his walking
distance was stable around 600 m.
At start of ERT, the median percentage of the predicted
distance walked (6MWT-PP) was 79% (range 32–91%). To
describe changes over time at group level, a statistical model
was generated. Over 7 years of ERT, the mean 6MWT-PP
increased significantly by 7.4%-points (pp) (Fig. 1a; 95% con-
fidence interval (CI) 2.4 pp–12.3 pp.; p < 0.001).
Fifteen patients performed QMFT measurements. At start
of ERT, the median QMFT score was 92% (range 44–100%).
Mean QMFTscores improved in the first 2 years of treatment,
and then stabilized (Fig. 1b). After 7 years of treatment, scores
had increased significantly by 9.2 pp. (CI 1.8 pp–16.6 pp.; p =
0.006).
Supplemental Fig. 2 displays the individual measurements
of the patients in combination with the group mean.
Muscle strength
Fourteen patients performed HHD measurements. At start of
treatment, the median HHD score was 57% (range 15–70%).
Mean HHD scores tended to improve over time (Fig. 1c), but
were not significantly better at 7 years than at start of ERT
(+17.8 pp.; CI -3.4 pp. – 39.0 pp.; p = 0.14). HHD scores
within individual patients showed considerably large varia-
tion, which may explain this.
MRC measurements were available for all 17 patients. At
start of ERT, median MRC values were 91.7% (range 10–
99%).Most patients had close to maximalMRC scores, which
they were able tomaintain during follow-up, thereby introduc-
ing a ceiling-effect. At group level, mean MRC scores did not
change significantly over 7 years of treatment (Fig. 1d: differ-
ence of −1.3 pp.; CI -0.7 pp. – 3.28 pp.; p = 0.34).
Lung function
Lung function could be tested reliably in sitting position
in 16 patients, and in supine position in 14 patients. At
start of ERT, median FVC scores in sitting position
were 87% (range 16–104%) and 85% in supine position
(range 39–109%). In sitting position, five of 16 patients
had a reduced FVC (<80%), compared to seven at the
last follow-up measurement. Two of these patients could
not be tested supine. Five of the remaining 14 patients
had a reduced FVC in supine position at the start and
seven at the last follow-up. At start of ERT, three pa-
tients needed respiratory support: two used non-invasive
ventilation, and one required invasive ventilation and
was ventilated for 24 h/day throughout follow-up. No
patients started respiratory support during follow-up.
At group level, lung function in sitting position de-
clined significantly over time (Fig. 2a; −5.2 pp. atTa
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7 years of ERT; CI 0.05–10.4 pp.; p = 0.047). In supine
position a similar trend was observed but this was not
statistically significant (Fig. 2b; −4.7 pp.; CI -4.5 to
13.9; p = 0.34). In sitting position, 331 measurements
were available in 16 patients; in supine position, 253
assessments were available for 14 patients, reducing sta-
tistical power and possibly explaining the difference in
statistical significance.
Further examination of FVC in sitting position re-
vealed a difference between male and female patients
(Fig. 2c and d). In males it decreased over time
(−8.1 pp. at 7 years ERT; CI 0.9–15.3 pp.; p = 0.018),
while females remained stable (+1.0 pp. at 7 years of
ERT; CI -7.03 to 9.12; p = 0.80). This difference was
not detected in supine position, possibly due to the
lower statistical power.
Individual responses to treatment
In addition to the analyses at group level, we also assessed indi-
vidual patients’ progression on the outcome measures during
treatment (Fig. 3). In general, patients’ motor outcomes
responded better than their lung function. Motor outcomes im-
proved or stabilized in 71–93% of patients, whereas lung func-
tion improved or stabilized in 56–69%. As these results reflect
human judgment, and as follow-up time varied between patients,
they should be interpreted with caution. The clinical relevance of
an increase or decrease was not included in this assessment: a
change from 100 to 85% FVC, which is still in the normal range,
and from 70 to 50% FVC were both categorized as decline.
In sitting position, five patients had an FVC below 80% at
start of treatment. Three of these patients improved or stabilized
during treatment. For example, patient 15, who required nightly
Fig. 1 Predicted group means for
motor outcomes over time. Group
mean (black line) of the outcome
measures and 95% prediction
interval (gray area) obtained using
linear mixed models. The
difference (Δ) between baseline
and 7 years of ERT, and the
corresponding p-value, are shown
on the right-hand side of the fig-
ures. Number of measurements
available for analysis of the
6MWT: 199, QMFT: 296, HHD:
221, and MRC: 232. N = number
of patients participating in
analysis
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BiPAP, had an initial FVC score in sitting position of 57%which
improved to 71% after almost 7 years of treatment. On the other
hand, five of the 11 patients whose FVC in sitting position was
above 80%, deteriorated. For example, patient 3 improved in the
first 2 years of therapy, but then declined from 115 to 88%.
Similarly, patients with good initial motor outcomes were occa-
sionally seen to decline and some with poor initial outcomes
improved. In the most severely affected patient (pt.10), who can
be classified as an atypical infantile patient (Slonim et al 2000)
and started ERT 6 years after becomingwheelchair and ventilator
dependent, ERT only seemed to have an effect on the heart.
Discussion
This study presents the follow-up of 17 patients with non-classic
presentations of Pompe disease who had started ERT during
childhood. After 7 years of treatment, there were group-level
improvements in the QMFT and in the distance walked
(6MWT), while the MRC and HHD seemed to remain stable.
For a progressive disorder in which all these outcomes are antic-
ipated to decline (Wokke et al 2008; van Capelle et al 2010; van
der Ploeg et al 2010; van der Beek et al 2011; deVries et al 2012;
van der Beek et al 2012), these results demonstrate that ERT has
a positive effect in children.
The improvement in the QMFT is extremely relevant to
patients, since this test measures the ability to perform
everyday movements that are particularly difficult for
Pompe patients, such as squatting, raising the hands
above the head, or doing a sit-up. For two reasons, we
believe that our results are robust: we included a relatively
large group of children who were followed over a long
period, and the observed effects were sustained despite
multiple testing correction. While patients’ individual re-
sponse patterns support these results, they also indicate
that not all patients benefit equally from treatment.
Fig. 2 Predicted mean FVC
scores over time. Group mean
(dark line) of the outcome
measures and 95% prediction
interval (gray area) obtained using
linear mixed models. The
difference (Δ) between baseline
(dotted line) and 7 years of ERT,
and the corresponding p-value,
are shown on the right-hand side
of the figures. The trend of FVC
scores in sitting position differed
for males and females. They have
therefore been plotted separately
in panels C and D. Number of
measurements available for anal-
ysis of FVC in sitting position:
331 and of FVC in supine posi-
tion: 253. N = number of patients
participating in analysis
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Generally, patients’ motor outcomes responded better com-
pared to their pulmonary function. The poorer response with
regard to lung function might be due to the involvement of the
diaphragm (Pellegrini et al 2005; Prigent et al 2012; Gaeta et al
2013; Wens et al 2015; Mogalle et al 2016). This involvement is
also illustrated by the fact that fewer patients were able to per-
form lung-function assessments in supine position. Our statistical
analyses show that lung function declined significantly in sitting
position, and tended to decline in supine position. These declines
were similar in extent (4-5 pp. over 7 years). In untreated adult
patients and children, FVC has been reported to decline between
1 pp. and 5.5 pp. per year (Wokke et al 2008; van Capelle et al
2010; van der Ploeg et al 2010; van der Beek et al 2011; de Vries
et al 2012; van der Beek et al 2012). This is greater than the
decline we observed over 7 years, suggesting that disease pro-
gression in terms of lung function slows down during ERT.
Our results also suggest that males responded more poorly
with regard to lung function than females. However, this dif-
ference needs to be interpreted with caution, since there were
fewer females than males, and since this difference could be
demonstrated in sitting position only. Nevertheless, a similar
trend in gender difference was reported in the multicenter
randomized placebo-controlled study in 90 adult patients with
Pompe disease (van der Ploeg et al 2010). It should be inves-
tigated whether such gender differences truly exist.
The individual response to treatment varied considerably be-
tween patients, and it would be very relevant to identify its
causes. In general, treatment success is believed to be correlated
with an early start of treatment, i.e., when patients are still mildly
affected. We found that this paradigm does not hold for all pa-
tients: some patients with clearly reduced pulmonary and/or mo-
tor function improved or stabilized, while some whose initial
clinical status was good deteriorated on ERT.
Other factors that could be involved in the response to ERT
are the type of mutation in the GAA gene, genetic background
factors such as the ACE polymorphisms (Ravaglia et al 2012; De
Filippi et al 2014; Baek et al 2016), or antibodies against ERT
with alglucosidase alfa. For five of our patients we have 3 years
of data on antibody titers; in all five, these were low (van Capelle
et al 2010). It was also shown in adult patients that the vast
majority had low antibody titers, while a counteracting effect
was demonstrated only in incidental cases (de Vries et al 2017).
All in all, more research is needed to fully understand and predict
which patients respond well to treatment and which do not.
Patients responding less well to ERT might benefit from new
or personalized treatment options.
Noteworthy, 14 of the 17 children (82%) in our study had
the same common genotype, the c.-32-13 T > G GAA gene
variant in combination with a null allele, as found in over
90% of the Caucasian adult Pompe patients. This highlights
that the group of patients with the c.-32-13 T > G/‘null’ GAA
genotype represent a broad clinical spectrum.
Some outcome measures could not be assessed in all wheel-
chair and/or ventilator dependent patients. The 6MWT can only
be performed in patients who are able to walk, and the results
may therefore not be generalizable to the most severely affected
patients. This is also partly true for the QMFT and FVC.
Few studies have been published on the effects of ERT in
children. Studies on late-onset patients occasionally include chil-
dren: a review from 2013 identified 27 children amongst 368
patients in 21 papers (Toscano and Schoser 2013). However,
most of these studies do not provide separate information on
children. Supplemental Table 2 summarizes the results of eight
publications that report on the outcomes of children treated with
ERT (Winkel et al 2004; Rossi et al 2007; van Capelle et al 2008;
Bembi et al 2010; van Capelle et al 2010; Ishigaki et al 2012;
Deroma et al 2014; Porta et al 2015). The number of children
included per study ranged from one to eight; follow-up ranged
from 1.3 to 8 years (in most studies, follow-up was around 3–
4 years). These studies suggest that patients’motor function and
muscle strength tend to improve, and their lung function is stable
or possibly improves. The present study, which describes long-
Fig. 3 Individual patients’
response on the different outcome
measures
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term findings, is partly in line with this. Upon analysis of the
individual follow-up of five of our patients who had previously
been described after 3 years of treatment, we found that, with
longer follow-up (up to seven more years in the current study),
two had started to decline, while the others had continued to
improve or to stabilize (van Capelle et al 2010). These observa-
tions stress the continuing importance of regular long-term pa-
tient follow-up.
Conclusion
Pompe disease is a progressively deteriorating disease. We
observed that ERT had a clearly positive effect in our cohort
of children, most of whose muscle strength and function
remained stable or improved during treatment. At group lev-
el, response to treatment was better for motor outcomes than
for lung function. There were large individual differences
between patients in the response to treatment. For some
patients new or personalized treatment options need to be
considered.
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